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 Supplementary Table 1. Characteristics of all human IGF-PCa studies used for circulatory and genetic meta-analyses, stratified by study design and ordered by year of publication. 
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Prospective studies                                         
Chan (1998) Physicians' Health Study USA ELISA Mixed PBC   M 5yr 60.3 7 Not Stated √ √     √       Quantiles1 √ Moderate 
Harman (2000) Baltimore Longitudinal 
Study of Aging 
USA RIA Healthy PBC 74 64.8 65.7 12.8 Multi-
ethnic 
√ √     √       Quantiles √ Moderate 
Stattin (2000) NSHDS Sweden IRMA Mixed PBC 63 59.7 59.6 3.3 Caucasian √   √ √ √       Quantiles √ Moderate 
Stattin (2001) NSHDS Sweden IRMA Mixed PBC   58.4 59.5 3.9 Caucasian √       √       None: RCD √ Moderate 
Chan (2002) Physicians' Health Study USA ELISA Healthy PBC   M 1yr M 1yr 9 Not Stated √       √       None: RCD √ Moderate 
Li (2003)   USA ELISA Mixed S   61.3 62.8 2 Multi-
ethnic 
√       √   √   Quantiles √ Moderate 
Woodson 
(2003) 
ATBC Trial Finland ELISA Healthy TC 68.6 59 56.4 9.6 Not Stated √       √       Quantiles √ Moderate 
Janssen (2004) ERSPC Netherlands IRMA Healthy TC 66.4 62.3 62.3 4 Not Stated √       √     √ None: RCD √ Moderate 
Stattin (2004) NSHDS Sweden IRMA Mixed PBC 63.6 59.9 59.9 3.7 Caucasian √       √       Quantiles √ Moderate 
Chen (2005) Cardiovascular Health Study USA IRMA Mixed PBC   72.3 72.3 3.4 Multi-
ethnic 
√       √   √   Quantiles √ Moderate 
Meyer (2005) SUVIMAX Trial France CLA Healthy TC   55.2 55.2 5+ Not Stated √ √   √ √       Quantiles √ Moderate 
Platz (2005) Health Professionals Follow 
Up Study 
USA ELISA Healthy PBC 68.6 68.6 M 1yr 2.2 Not Stated √       √   √   Quantiles √ Moderate 
Morris (2006) BUPA study UK ELISA Healthy PBC   52.4 52.4 9.7 Not Stated √ √     √       Means   Moderate 
Severi (2006) Melbourne collaborative 
cohort 
Australia ELISA Mixed PBC 67     3+ Multi-
ethnic 
√       √       Excluded   Critical 
Allen (2007) EPIC Europe ELISA Mixed PBC 65     3.4 Multi-
ethnic 
√       √   √   Quantiles √ Moderate 
Li (2007) Physicians' Health Study USA ELISA Mixed PBC 69.4 58.9 59 11 Caucasian  √       √       Means √ Moderate 
Weiss (2007) PLCO screening trial USA ELISA Healthy PBC   >55 >55 1+ White √       √   √ √ Quantiles √ Moderate 
Mikami (2009) Japan Collaborative Cohort 
Study 
Japan IRMA Mixed PBC   69.3 69.1 5.3 Asian √       √       Means √ Moderate 
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Gu (2010) BPC3   ELISA Mixed PBC   62.3 63.2 4.5 Caucasian √       √       None: RCD √ Moderate 
Nimptsch 
(2011) 
Health professionals follow 
up study 
USA ELISA Mixed PBC 65 M 1yr M 1yr 6 Multi-
ethnic 
√       √   √   Continuous √ Moderate 
Price (2012) EPIC Europe ELISA Mixed PBC   60.12 60.1 3.4 Not Stated √           √   Quantiles √ Moderate 
Tsilidis (2012) BPC3   ELISA Mixed PBC   62.9 60.2 4.9 Caucasian √       √       None: RCD √ Moderate 
Tsilidis (2013) BPC3   ELISA Mixed PBC   66.2 65.9 2.1 Caucasian √       √ √     None: RCD √ Moderate 
Muhlbradt 
(2014) 
Physicians' Health Study USA ELISA Mixed PBC 70 62 8 Caucasian  √               Quantiles2 √ Moderate 
Retrospective studies                                         
Cohen (1993)   USA RIA Healthy P Not stated     Not Stated √ √   √ √       Means √ Moderate 
Kanety (1993)   Israel RIA Healthy NS   65.8 56.4 23m Not Stated       √ √       Excluded   Critical 
Ho (1997)   Australia RIA Mixed H   74.4 68.6   Not Stated √ √   √ √       Excluded   Critical 
Mantzoros 
(1997) 
  Athens, Greece RIA Healthy P   71.9 71.8   Not Stated √               Continuous √ Moderate 
Wolk (1998)   Sweden IRMA Healthy P   70 M 
10yrs 
  Not Stated √       √   √   Quantiles, 
Continuous  
√ Serious 
Schaefer (1998)   USA RIA Healthy P 71     1+ Not Stated √               Rowlands 
data 
  Unclear 
Cutting (1999)   UK IRMA Healthy H   73.2 67.4   Not Stated √               Excluded   Critical 
Djavan (1999)   Austria IRMA Mixed H   65.7 67.7   White √               Means   Serious 
Signorello 
(1999) 
  Sweden IRMA Mixed P   69.9 70.9   Not Stated √   √   √       Means √ Moderate 
Hill (2000)   Czech Republic IRMA BPH H   77.1 72.2   Not Stated √               Means   Serious 
Koliakos (2000)   Greece IRMA BPH H   67 69   Not Stated √               Means   Serious 
Baffa (2000)   USA ELISA Healthy NS Not stated     Not Stated √               Means √ Moderate 
Finne (2000) Finnish Prostate Cancer 
Screening Trial 
Finland ELISA Mixed PBC   62 62.6 2-
18m 
Not Stated √       √     √ Continuous √ Moderate 
Kurek (2000)   Germany CLA Healthy NS   66.2 64.5   Not Stated √               Means √ Moderate 
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Lacey (2001)   USA ELISA Healthy PBC 70.6       White √       √       Means √ Moderate 
Chokkalingham 
(2001) 
  China ELISA Mixed P   71.9 72   Asian √ √ √   √       Quantiles √ Moderate 
Khosravi (2001)   Canada ELISA BPH NS   64.8 65.6   Not Stated √       √       Means   Serious 
Li (2001)   China RIA Mixed H   74.7 74.8   Asian √               Quantiles   Moderate 
Perk (2001)   Turkey IRMA Healthy H   62.3 36   Not Stated √               Excluded   Critical 
Ismail (2002)   Montreal, 
Canada 
ELISA Mixed H   64.6 64.5   Not stated √       √       Means √ Serious 
Shariat (2002)   USA ELISA Healthy H 63 29 44   Not Stated √     √ √       Rowlands 
data 
  Unclear 
Peng** (2002)   China IRMA Mixed     74.8 64.8   Not Stated √               Excluded   Critical 
Kaaks (2003) NSHDS Sweden RIA Mixed PBC       1m-
10yrs 
Caucasian √               None: RCD   Moderate 
Miyata (2003)   Nagasaki 
University, 
Japan 
IRMA BPH H   70.9 69.8   Asian √       √   √   Means   Serious 
Scorilas (2003) Padova Italy ELISA BPH H   68 65   Not Stated √               Means   Serious 
Aksoy (2004)   Turkey IRMA BPH NS   53-85 51-79   Not Stated √       √   √   Means   Serious 
Oliver (2004) ProtecT UK ELISA Mixed PBC   62.2 62.2   Caucasian √ √   √ √   √ √ Quantiles √ Moderate 
Trapeznikova 
(2004) 
  Russia ELISA BPH NS   66.6 60.3   Not Stated √ √             Excluded   Critical 
Lopez (2004)   Malaysia ELISA Healthy NS   69.7 57.2   Not Stated √       √       Excluded   Critical 
Kehinde (2005)   Kuwait/Oman IFMA Healthy P 69.7 15-90 15-90   Caucasian √       √       Excluded   Critical 
Marszalek 
(2005) 
  Austria IRMA Mixed NS 66.7 67 69   Not Stated √               Means   Moderate 
Nam (2005) University Health Network Canada ELISA Mixed TC   66.6 65.5   Multi-
ethnic 
√       √       Means   Serious 
Trojan (2006)     ELISA BPH H   62.8 66.8   Not Stated   √             Means   Serious 
Hernandez 
(2007) 
  USA Other Healthy H   65.86 68.85   Black √       √ √ √   Quantiles √ Moderate 
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Zhigang (2007)   China ELISA Mixed H   65.5 65.1   Asian √       √       Means   Moderate 
Borugian (2008) Prospective Multiethnic 
Study 
Hawaii, USA, 
Canada 
ELISA Mixed P   69.1 68.9 1+ Multi-
ethnic 
√       √       Quantiles √ Moderate 
Hong (2008)   Korea IRMA Healthy H   65 64   Asian √       √       Means   Serious 
Sciarra (2008)   Italy ELISA BPH H   67.24 67.06   Not Stated √               Means   Serious 
Jeong*** 
(2009) 
  Korea ELISA Healthy P   63.5 63.1   Asian √       √   √   Quantiles √ Moderate 
Pina (2009)   Portugal ELISA BPH NS   69 67   Not Stated √               Means   Serious 
Johansson 
(2009) 
CAPS Study Sweden   Healthy P   M 5yr M 5yr   Caucasian         √ √     Means √ Moderate 
Gill (2010) MEC USA ELISA Mixed P   68.9 68.7   Multi-
ethnic 
√ √ √   √   √   Quantiles √ Moderate 
Kim (2010)   Korea ELISA Mixed H Not stated   Not Stated       √ √       Rowlands 
data 
√ Moderate 
Park*** (2010)   Korea ELISA Healthy H   64.7 63.5   Asian         √ √     Means √ Moderate 
Tajtakova 
(2010) 
  Slovakia RIA Healthy NS   65.5 60.7   Not Stated √       √       Means   Serious 
Campa (2011) EPIC Europe ELISA Mixed PBC 60.4 60.4 60.5 1* Caucasian  √       √       None: RCD   Moderate 
Darago (2011)   Poland CLA BPH H   70.2 70.1   Not Stated √       √       Means   Serious 
Safarinejad 
(2011) 
  Iran ELISA Healthy H   63.6 62.5   Caucasian √       √ √     Means √ Moderate 
Rowlands 
(2012) 
ProtecT UK RIA Mixed PBC   61.9 61.7   White  √ √   √ √     √ Continuous √ Moderate 
Neuhouser 
(2013) 
PCPT  USA ELISA Mixed TC   63.6 63.6   White √ √   √ √     √ Means √ Moderate 
Iltaf (2013)   Karachi ELISA Healthy P     50+   Asian √               Excluded   Critical 
Genetic data only                                         
Ho (2003)   USA   Mixed H 63       Multi-
ethnic 
          √     Categorical √ Low 
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Wang (2003)   Japan   Healthy P         Multi-
ethnic 
          √     Categorical √ Low 
Li (2004)   USA   Mixed           Multi-
ethnic 
          √     Categorical √ Low 
Friedrichsen  
(2005) 
Seattle-Puget Sound 
Registry SEER  
USA   Mixed P         Multi-
ethnic 
          √     Categorical √ Low 
Neuhausen  
(2005) 
  University of 
Utah, USA 
  Mixed P 63       Multi-
ethnic 
          √     Categorical √ Unclear 
Schildkraut 
(2005) 
  USA   Mixed P 62.7       Multi-
ethnic 
          √     Categorical √ Unclear 
Tsuchiya (2005)   Japan   Healthy H         Caucasian           √     Categorical √ Low 
Chen (2006) Cardiovascular Health Study USA   Mixed PBC         Multi-
ethnic 
          √     Categorical √ Low 
Cheng (2006) MEC USA   Mixed PBC         Caucasian           √     Categorical √ Unclear 
Cheng (2006) MEC USA   Mixed PBC 68.3       African-
American 
          √     Categorical   Unclear 
Hoyo (2007)  USA   Mixed H         Multi-
ethnic 
          √     Categorical √ Low 
Johansson 
(2007) 
CAPS Study Sweden   Healthy P         Caucasian           √     Categorical   Unclear 
Sarma (2008) Flint Men's Health Study USA   Mixed P         Asian           √     Categorical √ Critical 
Schumacher 
(2010) 
BPC3  Mixed ELISA Mixed PBC 68       Asian           √     Categorical √ Low 
BPH: Benign prostatic hyperplasia; M: Matched; H: Hospital; P: Population; PBC: Population-based cohort; RCD: Repeated cohort data; S: Sibling; TC: Trial cohort. 
ATBC: Alpha-Tocopherol, Beta-Carotene Cancer Prevention; BPC3: NCI Breast and prostate cancer consortium; CAPS: Cancer of the Prostate in Sweden; EPIC: European Prospective Investigation into Cancer and Nutrition; 
MEC: Multi-ethnic cohort; NSHDS; Northern Sweden Health and Disease Cohort Study; PCPT: Prostate cancer prevention trial; PLCO: Prostate, Lung, Colorectal and Ovarian. 
*Minimum number of years between sample collection and diagnosis. 
**Unclear if retrospective or prospective study; therefore, grouped as retrospective 
***Unclear whether PSA-screened or not. 
1IGF-I only 
2RFPC study only 
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Supplementary Table 2. List of polymorphisms presented in each genetic paper (highlighted columns represent those polymorphisms with sufficient data to be analysed. 
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Chen (2006) √ 
                       
√ √ 
          
√ 
           
Cheng (2006) 
                                    
√ 
           
Cheng (2006) 
 
√ √ √ √ 
 
√ √ 
 
√ 
 
√ √ √ 
 
√ √ √ √ √ 
  
√ √ 
                        
Friedrichsen (2005) √ 
                                         
√ 
     
Hernandez (2007) √ 
                     
√ 
             
√ 
           
Ho (2003) 
                          
√ 
                     
Hoyo (2007)** √ 
                                   
√ 
           
Johansson (2009) 
                               
√ √ √ √ √ 
  
√ 
 
√ √ 
 
√ 
   
√ 
Johansson (2007) 
          
√ 
         
√ √ 
                          
Li (2004)** √ 
                    
√ 
              
√ 
           
Neuhausen (2005)** √ 
                                               
Park (2010) 
                                    
√ 
           
Safarinejad (2011) 
                                    
√ 
           
Schildkraut (2005) √                                    √      √      
Schumacher (2010) 
              
√ 
                                 
Tsilidis (2013) 
     
√ 
  
√ 
                  
√ √ √ √ 
      
√ 
 
√ 
   
√ √ √ √ 
 
Tsuchiya (2005) √ 
                                               
Wang (2003) 
                                    
√ 
           
*Only IGF-1(CA)n and IGFBP-3 -202A/C were meta-analysed. 
**Could not be used in meta-analysis as data was un-combinable (Li (2004) had combinable IGFBP-3 data, but un-combinable IGF-I data) 
 
  
Supplementary Table 3: Studies investigating tissue expression of IGF system and prostate cancer included as supporting evidence. 
Study  Year Experiments Samples Statistical analysis  Results 
IGF-I 
Mita  2000 qPCR analysis of mRNA of IGF 
system  
24 prostatectomy specimens 
after neoadjuvant hormone 
therapy 
 
No controls included.  
Mann-Whitney U-test IGF-I mRNA was lower in locally advanced prostate cancer 
than in early stage (p=0.038), but was not related to LN 
mets, histologic differentiation or serum PSA level. 
Cardillo  2003 IHC, ISH and qPCR of IGF-I, IGF-II 
and IGF-IR protein and mRNA 
expression in PCa, PIN and NAP  
Prostatectomy specimens 
 
Control: PIN and NAP 
Mean +/- SEM, Chi-square, 
Student’s paired t-test, Mann-
Whitney U-test, Spearman rank 
correlation and linear regression 
, ANOVA  
IGF-I protein increased from NAP tissue to PIN, to PCa 
tissue in the epithelial (p<0.0001) and stromal (p<0.0146).  
 
No correlation between IGF-I (protein and mRNA) and 
Gleason histological score or TNM stage.  
Soulitzis  
 
2006 qPCR to determine mRNA 
expression levels of IGF-I in tissue 
specimens from patients with PCa, 
or BPH, and normal prostate 
samples obtained post-mortem 
from young individuals 
Patients with PCa (n=42) 
BPH: (n=42)  
Controls: young individuals 
(n=10)  
Chi-squared test and Fisher’s 
exact test  
PCa patients with low Gleason score (<7) have increased 
IGF-I (p=0.031) mRNA levels. IGF-I levels are also elevated 
in tumors with TNM stages T1-T2 (p=0.03). 
 
Massoner  2011 IHC and qPCR of IGF axis (IGF-I, 
IGF-II, IGFBP 1-6 and insulin 
receptor) in microdisseced tissue 
specimens of local PCa 
Set 1: 20 local PCa specimens 
assigned according to their 
Gleason score used for laser 
microdissection 
 
Set 2: 10 local PCa specimens 
 
Set 3: 22 samples for IHC 
together with 20 samples from 
set 1 
 
Benign tissues (from 
prostatectomy specimens) 
 
Spearman’s p test for 
correlation, Mann-Whitney U-test 
and student’s t-test 
IGF-I mRNA expression was decreased in prostate cancer 
compared with benign prostate areas.  
IGF-I mRNA was decreased in high-grade (GSC 8–10) 
compared with low- grade (GSC 5– 6) cancer.  
IGF-I protein levels determined by IHC do not reflect mRNA 
expression levels in PCa.   
Savvani  2013 IHC of IGF-IEc expression in 
prostate cancer specimens  
83 prostatectomy specimens  
No controls  
Shapiro-Wilk test, Student’s t-
test,  ANOVA and spearman 
correlation coefficient  
Mean IGF-1Ec expression was lower in localized (stage 
≤IIb) PCa compared to locally advanced tumours (stage 
≥III) (p=0.004).  
Weak positive correlation was observed between IGF-IEc 
expression and Gleason score (p=0.02). 
No association between IGF-IEc expression and age 
(p=0.81), PIN (p=0.153), positive surgical margins (p=0.95), 
vascular invasion (p=0.347), perineural invasion (p=0.185) 
and tumour extent inside the prostate gland        (p=0.18).  
 Study  Year Experiments Samples Statistical analysis  Results 
IGF-II 
Tennant  1996 IHC and ISH to compare the 
expression of IGF-IR and IGF-II in 
benign epithelium, HG-PIN and 
prostate adenocarcinoma  
32 prostatectomy specimens  ANOVA, Fisher’s exact 
test and paired t-tests 
IGF-II mRNA was increased by 30% in adenocarcinoma 
compared to benign epithelium (p<0.03) but not IGF-II 
protein.  
Mita  2000 qPCR analysis of mRNA of IGF 
system  
24 prostatectomy specimens after 
neoadjuvant hormone therapy; No 
controls included.  
Mann-Whitney U-test IGF-II mRNA was associated with pathologic stage 
(p=0.003), LN mets (p=0.0007), histologic differentiation  
(p=0.003) and serum PSA level (p=0.04) after hormone 
therapy. 
Cardillo  2003 IHC, ISH and qPCR of IGF-I, IGF-II 
and IGF-IR protein and mRNA 
expression in PCa, PIN and NAP  
Prostatectomy specimens 
 
Control: PIN and NAP 
Mean +/- SEM, Chi-
square, Student’s paired t-
test, Mann-Whitney U-test, 
Spearman rank correlation 
and linear regression and 
ANOVA  
 
 
IGF-II protein increased as the prostate tissue progressed 
from NAP, to PIN and PCa in both epithelium (p<0.0001) 
and stroma (p=0.033).  
 
IGF-II mRNA increased as the prostate tissue progressed 
from NAP, to PIN and PCa in the epithelium (p<0.0001) and 
in the stroma (p=0.04). 
No correlation was found between TNM stage and IGF-II 
expression. 
High Gleason score tumors (8,9) expressed IGF-II mRNA 
and protein more strongly than lower Gleason score tumors, 
in the epithelium (IGF-II protein 2.85±0.14 vs 1.90±0.28, 
p=0.012; IGF-II mRNA 2.62±0.10 vs 1.96±0.22, p=0.03) and 
in the stroma (IGF-II protein 2.71±0.18 vs 2.06±0.22, p = 
0.048; IGF-II mRNA 2.23±0.1 vs 1.69±0.2, p=0.05). 
 
Massoner  2011 IHC and qPCR of IGF axis (IGF-I, 
IGF-II, IGFBP 1-6 and insulin 
receptor) in microdisseced tissue 
specimens of local PCa 
Set 1: 20 local PCa specimens 
assigned according to their Gleason 
score used for laser microdissection; 
Set 2: 10 local PCa specimens; Set 3: 
22 samples for IHC together with 20 
samples from set 1 
 
Control: Benign tissues (from 
prostatectomy specimens) 
Spearman’s p test for 
correlation, Mann-Whitney 
U-test and student’s t-test 
IGF-II mRNA expression was decreased in PCa compared 
with benign prostate areas. 
IGF-II mRNA was decreased in high-grade (GSC 8–10) 
compared with low- grade (GSC 5– 6) cancer.  
IGF-II protein levels determined by IHC do not reflect mRNA 
expression levels in PCa.   
 
 
 Study  Year Experiments Samples Statistical analysis  Results 
IGF-IR 
Tennant  1996 IHC and ISH to compare the 
expression of IGF-IR and IGF-II in 
benign epithelium, HG-PIN and 
prostate adenocarcinoma 
32 prostatectomy specimens  ANOVA, Fisher’s exact 
test and paired t-tests 
IGF-IR mRNA and protein was decreased in PIN and in 
PCa compared to benign epithelium (mRNA: p<0.0001; 
protein: p<0.0004).  
Cardillo 2003 IHC, ISH and qPCR of IGF-I, IGF-II 
and IGF-IR protein and mRNA 
expression in PCa, PIN and NAP 
Prostatectomy specimens 
 
Control: PIN and NAP 
Mean +/- SEM, Chi-
square, Student’s paired t-
test, Mann-Whitney U-test, 
Spearman rank correlation 
and linear regression and 
ANOVA  
IGF-IR mRNA expression increased from NAP to PIN to 
PCa in the epithelial (p<0.0001) and stromal (p=0.001).  
IGF-IR protein increased in PCa than PIN and normal 
epithelial cells (p<0.0001) 
Ryan  2007 IHC of IGF-IR expression in normal 
prostate epithelium and prostate 
cancer specimens 
30 primary prostate tumours 
5 locally recurrent androgen-
independent tumors; 5 distant 
androgen-independent lymph node 
metastases  
Control: benign prostates from men 
without PCa 
Mann Whitney test and 
Fisher exact test  
IGF-IR protein was expressed in both normal prostate 
epithelium and PCa.  
No associations between the Gleason grade and absence 
or presence of the IGF-IR (p =0.17 for normal epithelium in 
men with cancer; p= 0.26 for PCa).  
No associations observed between stromal staining and 
tumour stage (T1c vs. T2–T4, P =1.0), race (white vs. non- 
white, P=0.71), age (P= 0.49), or PSA level (P= 0.56). 
Massoner  2011 IHC and qPCR of IGF axis (IGF-I, 
IGF-II, IGFBP 1-6 and insulin 
receptor) in microdisseced tissue 
specimens of local PCa 
Set 1: 20 local PCa specimens 
assigned according to their Gleason 
score used for laser microdissection; 
Set 2: 10 local PCa specimens; Set 3: 
22 samples for IHC together with 20 
samples from set 1 
 
Control: Benign tissues from the 
prostatectomy specimens 
Spearman’s p test for 
correlation, Mann-Whitney 
U-test and student’s t-test 
IGF-IR mRNA was decreased in PCa compared with benign 
epithelial cells.  
. 
  
Turney  2011 IHC of IGF-IR expression in serial 
prostate cancer specimens  
18 patients who had undergone serial 
channel TURP at least 3 months 
apart.  
Controls: prostate cancer sections that 
had previously stained heavily for IGF-
IR 
Not stated No correlation between Gleason sum score and IGF-1R 
protein.  
6/7 patients with falling IGF-1R staining scores were 
responding to androgen deprivation therapy (confirmed by 
PSA response) between operations. 7/8 patients who had 
progression to androgen-independence between 
procedures, IGF-1R levels increased or remained high.  
7/11 patients developed radiologically confirmed 
metastases between procedures showed stable or 
increasing IGF-IR staining. 
 
Study  Year Experiments Samples Statistical analysis  Results 
IGF-IR (Continued) 
Hetzl 2012 IHC of IGF-IR expression in both 
prostatic stromal and epithelial.  
45 prostatic samples from PCa 
patients obtained by radical 
prostatectomy 
Control: 15 prostatic samples were 
obtained from necropsied patients 
without a diagnosis of prostatic or 
other urological diseases 
ANOVA and post-hoc 
Tukey’s test 
Increased IGF-IR protein levels in PCa and HG-PIN 
compared to normal and BPH group (p<0.01).  
Zu  2013 IHC of IGF-IR expression in PCa to 
investigate if IGF-IR is a potential 
effect modifier for the association 
between PTEN expression and 
lethal prostate cancer risk. 
651 men with PCa Logistic regression 
multivariate Cox models and 
Wald test 
High IGF-IR protein alone was associated fatal prostate 
cancer or distant metastasis (HR:13.8; 95% CI, 1.7–112.8). 
A significant negative interaction between PTEN and IGF-IR 
was found (Pinteraction=0.03). 
IGFBP-2 
Tennant  1996 IHC and ISH was carried out to 
compare expression of IGFBP-2 
and 3 in PCa and HG-PIN 
28 prostatectomy specimens from 
prostate adenocarcinoma 
Benign (n=28); HG-PIN (n=8);    
PCa (n=11) 
ANOVA, Fisher’s exact test, 
linear regression and paired 
t-tests 
IGFBP-2 protein and mRNA was increased in PIN 
(p<0.0003) and PCa (p<0.0003).  
Thrasher 
 
 
 
 
 
1996 IHC of IGFBP-2 and IGFBP-3 
protein expression in prostate 
tissues  
24 patients who underwent radical 
prostatectomy for localized prostate 
adenocarcinoma  
ANOVA and Fisher’s 
protected least squared 
difference post-hoc test : 
compare IGFBP-2 and 3 
among different groups. 
IGFBP-2 protein was increased in PIN  (p<0.001), and PCa  
(p<0.001) compared to normal epithelium and increased in 
PCa compared to PIN (p <0.05).  
No correlation between the stage and grade of prostate 
cancer and IGFBP-2 immunostaining intensity (p = 0.69 and 
0.48, respectively) 
No correlation between preoperative serum PSA 
determinations and IGFBP-2 immunoreactivity (p= 0.99) 
Figueroa  1998 IGFBP 1-6 RNA expression in 
benign and neoplastic prostate 
tissue  detected by RNAse 
protection assay  
23 consecutive radical 
prostatectomy specimens 
 
High Gleason scores (7-10): n=6; 
Low or intermediate scores (2-6): 
n=17 
Control: Benign prostate tissue  
(Note: samples obtained from the 
same prostatectomy specimens) 
 
One-tailed Student’s t-test Tumours with high Gleason score expressed higher IGFBP-
2 RNA levels (0.4555 (CI: 0.395-0.515) vs 0.3 (CI: 0.256-
0.356) (p<0.002).  
High Gleason score tumours had a 117% and 95% higher 
IGFBP-2/IGFBP-3 RNA expression ratio compared with 
benign and low grade tumours, respectively.  
 
Study  Year Experiments Samples Statistical analysis  Results 
IGFBP-2 (Continued) 
Mita  2000 qPCR analysis of mRNA of IGF 
system  
24 prostatectomy specimens after 
neoadjuvant hormone therapy 
 
No controls included.  
Mann-Whitney U-test IGFBP-2 mRNA was associated with pathologic stage 
(p=0.002),  LN Mets  (p=0.001), histologic differentiation 
(p=0.002) and serum PSA level (p=0.002) after hormone 
therapy.  
 
Ambriosini-
Spaltro  
2001 IHC of IGFBP-2 in normal 
epithelium, HG-PIN and Prostate 
adenocarcinoma 
Prostatectomy specimens (n=60)  
 
Group 1: Patients with bladder outlet 
obstruction 
Group 2: Patients hormonally 
untreated before surgery 
Group 3: Patients who underwent 
complete androgen ablation 3 months 
before surgery 
 
Control: HGPIN and normal 
epithelium 
ROC curves: % of positive 
neoplastic cells 
 
Wilcoxon signed rank test: 
% of +ve neoplastic cells  
 
Spearman rank test: 
Gleason scores, pathologic 
stages and IHC scores 
IGFBP-2 is expressed in the cytoplasm of untreated PCa 
and to a lesser extent in HG-PIN.  
 
IGFBP-2 is expressed in PCa and HG-PIN after complete 
androgen ablation, but to a lesser extent than in the 
untreated neoplasms.  
IGFBP-2 expression in the untreated specimens is lower in 
HG-PIN than in invasive PCa.   
 
IGFBP-2 was positive in PCa cases but not in benign 
prostatic tissues.  
 
No correlation between IGFBP2 with Gleason Grade or 
Tumour stage. 
Richardsen  2003 IHC of IGFBP-2 expression in high-
grade PIN, and PCa 
 
193 radical prostatectomy specimens 
from patients with localized prostate 
adenocarcinoma 
Controls: BPH (n=14)  
 
 
Fisher’s exact probability 
test 
 
Significant overexpression of IGFBP-2 in all instances of 
PIN and in more than 90% of cancers regardless of the 
grade. .  
The majority of cases with invasive carcinoma showed an 
overexpression of IGFBP-2 in >90% of the cancer cells. 
Extent and pattern of IGFBP2 expression was not 
correlated with Gleason grade. 
Massoner  2011 IHC and qPCR of IGF axis (IGF-I, 
IGF-II, IGFBP 1-6 and insulin 
receptor) in microdisseced tissue 
specimens of local PCa 
Set 1: 20 local PCa specimens 
assigned according to their Gleason 
score used for laser microdissection 
 
Set 2: 10 local PCa specimens 
 
Set 3: 22 samples for IHC together 
with 20 samples from set 1 
 
Benign tissues 
Note: samples obtained from the 
prostatectomy specimens) 
Spearman’s p test for 
correlation,  Mann-Whitney 
U-test and student’s t-test 
IGFBP-2 mRNA expression levels unchanged in prostate 
cancer tissue areas compared with benign prostate tissue 
areas. 
 
 
Study  Year Experiments Samples Statistical analysis  Results 
IGFBP-3 
Tennant  1996 IHC and ISH was carried out to 
compare expression of IGFBP-2 
and 3 in PCa and HG-PIN 
28 prostatectomy specimens from 
prostate adenocarcinoma 
Benign (n=28); HG-PIN (n=8); PCa 
(n=11) 
ANOVA, Fisher’s exact 
test, linear regression 
and paired t-tests 
IGFBP-3 mRNA was unchanged in benign epithelium, PIN 
and PCa. 
IGFBP-3 protein was increased in PIN (p<0.0001) but as 
decreased in malignant cells (p<0.0001).  
Thrasher 
 
 
 
 
 
 
 
 
 
 
 
1996 IHC of IGFBP-2 and IGFBP-3 
protein expression in prostate 
tissues  
24 patients who underwent radical 
prostatectomy for localized prostate 
adenocarcinoma 
ANOVA and Fisher’s 
protected least squared 
difference post-hoc test 
: compare IGFBP-2 and 
3 among different 
groups.  
IGFBP-3 protein was decreased in PCa carcinoma 
compared to normal epithelium (p <0.0001).  
IGFBP-3 protein increased in PIN compared to normal 
epithelium (p<0.001).  
No correlation between the stage and grade of prostate 
cancer and IGFBP-3 protein (p =  0.88 and 0.52, 
respectively)   
No correlation between preoperative serum PSA 
determinations and IGFBP-3 immunoreactivity (p=0.21). 
Figueroa  1998 IGFBP 1-6 RNA expression in 
benign and neoplastic prostate 
tissue detected by RNAse 
protection assay 
23 consecutive radical prostatectomy 
specimens 
 
High Gleason scores (7-10): n=6; Low or 
intermediate scores (2-6): n=17 
Control: Benign prostate tissue from the 
same prostatectomy specimens 
One-tailed Student’s t-
test 
IGFBP-3 RNA levels lower in high Gleason score tumours 
(p=0.05).  
Hampel  1998 IHC of IGFBP-3 in prostate 
adenocarcinoma 
Study 1: 20 neoplastic prostates; 
Control: 6 normal prostates obtained 
from patients undergoing 
cystoprostatectomy for bladder cancer  
Study 2: 24 radical prostatectomy 
specimens from patients with clinically 
localized prostate adenocarcinoma 
Control: 8 normal prostates from organ 
donors or from patients undergoing 
cysto-prostatectomy for bladder cancer.  
Conventional non-
parametric tests, 
including the Wilcoxon 
sign rank test and the 
Mann Whitney U test. 
Mixed model was fit to 
the repeated measures 
data 
 
IGFBP-3 protein was decreased in PCa compared to 
normal epithelium (p<0.0001).  
IGFBP-3 protein was not associated with Gleason grade, 
recurrence or LN mets.  
 
 
 
 
Study  Year Experiments Samples Statistical analysis  Results 
IGFBP-3 (Continued) 
Linos  2009 IHC of IGFBP-3 expression in 
prostatic adenocarcinoma samples 
199 prostatectomy 
specimens.  
 
No control specimens from healthy 
controls.   
No stated Cytoplasmic IGFBP-3 over expression was observed in 
119/199 (60%) of all tumors.  
Within the non-treated subgroup (n=144), cytoplasmic 
IGFBP-3 over expression correlated with high tumor 
Gleason grade (Gleason score of 7 or more) [65% high 
grade versus 48% low grade, p=0.042]. 
Trend towards advanced stage, with 66% advanced stage 
tumors over expressing IGFBP3 protein versus 51% organ 
confined tumors, p=0.10). 
Seligson  
 
2013 IHC of nuclear and cytoplasmic 
IGFBP-3 protein expression in PCa 
226 prostatectomy specimens of 
prostate adenocarcinoma obtained 
from randomly selected, hormone 
naïve patients 
Median Age: 65 (range: 46-76).  
Control: Matched benign 
(morphologically normal or 
hypertrophic) or in situ neoplastic 
lesions (PIN) obtained from 
prostate cancer patients 
Kruskal-Wallis and Mann 
Whitney U tests: differences 
between nominal 
clinicopathologic prognostic 
variables.  
 
Chi-squared test: association 
of dichotomized IGFBP-3 
versus nominal variables.  
 
Kaplan-Meier plots and Cox 
proportional Hazards 
regression models: 
association with recurrence-
free time.  
Higher IGFBP-3 cytoplasmic and nuclear staining in PCa 
than benign tissues (p<0.0001).  
Expression of nuclear IGFBP-3 was associated with 
disease recurrence as both a continuous p=0.0039, HR: 
1.03; 95% CI: 1.01-1.06) and a dichotomized (p=0.0033; 
2.51; 95% CI: 1.36-4.63) variable.  
Median recurrence-free time was 60 months for cases with 
high nuclear IGFBP-3 (n=71), and the median was not 
reached for cases with low nuclear IGFBP-3 (n=123) 
(Logrank p=0.0074).  
In patients with primary low-grade cancer, the presence of 
nuclear IGFBP-3 was even more predictive of tumor 
recurrence than in all cases (Logrank p=0.0007).  
In the low-grade group, IGFBP-3 mean positivity association 
with recurrence (p=0.0007, HR: 1.03; 95% CI: 1.03-1.10), 
and of dichotomized data (p=0.001; 5.44; 95% CI: 1.99-
14.87). 
Note: PCa: Prostate cancer; HG-PIN: High grade prostatic intraepithelial neoplasia; IHC: immunohistochemistry; ISH: in-situ hybridisation; NAP: normal adjacent counterpart; SEM: standard error of 
mean; qPCR: quantitative reverse-transcription polymerase chain reaction; BPH: Benign prostatic hyperplasia; ChIP: Chromatin immunoprecipitation; ab: antibody; ELISA: enzyme-linked 
immunosorbent assay; PSA: prostate specific antigen; TURP: transurethral resection of the prostate; MALDI-TOF: matrix-assisted laser desorption/ionization-time of flight; PCR: polymerase chain 
reaction; DRE: digital rectal examination; OR: Odds ratio; CI: confidence interval; LN mets: lymph node metastasis 
  
Supplementary Table 4: Studies investigating whether genetic or epigenetic changes in the IGF system is associated with prostate cancer 
Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGF-I 
Cheng  2006 Investigated whether 
genetic variation at the 
IGF-I locus is associated 
with prostate cancer risk. 
 
Sequencing: Men with 
advanced PCa (n=95)  
Genotyping Case-control 
study:   Men with PCa 
(n=2320) 
Controls: men without PCa 
(n=2290) 
Sequenced IGF-I exons in 
germline DNA 
Genotyping of tagged SNPs  
Unconditioned 
logistic regression: 
association between 
PCa and IGF-I 
haplotypes and 
genotypes and 
permutation tests 
Haplotype analysis revealed nominally statistically 
significant associations with PCa risk in each of the four 
haplotype blocks: haplotype 1B (OR = 1.21, 95% CI = 1.04 
to 1.40), haplotype 2C (OR = 1.24, 95% CI = 1.06 to 1.44), 
haplotype 3C (OR = 1.25, 95% CI = 1.03 to 1.50), and 
haplotype 4D (OR = 1.19, 95% CI = 1.02 to 1.39).  
SNP3 (rs7978742) and SNP4 (rs7965399) was associated 
with prostate cancer risk (Ptrend = .002). The CT genotype 
for SNP4 was associated with increased risk of prostate 
cancer, compared with the common homozygous TT 
genotype (OR = 1.25, 95% CI = 1.09 to 1.43; P = .001). 
This association was also statistically significant for non-
advanced disease (OR = 1.32, 95% CI = 1.13 to 1.55; 
P<0.001).  
Tsuchiya  2006 To examine the association 
of 13 genetic 
polymorphisms with 
survival of metastatic PCa 
patients.  
111 PCa patients with 
bone metastasis at 
diagnosis and not received 
treatment 
 
Polymerase chain reaction-
restriction fragment length 
polymorphism or automated 
sequencer with genotyping  
Kaplan-Meier curve, 
log rank test and cox 
proportional hazards 
model 
Long allele (over 18 [CA] repeats) of insulin-like growth 
factor-I (IGF-I) was significantly associated with a worse 
cancer-specific survival (P =0.025).  
Long allele of IGF-I polymorphisms was an independent 
risk factor for death (HR: 2.01: 95% CI: 1.12-3.62;p 
=0.019). 
Tsuchiya  2013 To evaluate the association 
of polymorphisms in 3 
linkage disequilibrium 
blocks of IGF-I on survival 
of metastatic PCa patients.  
215 patients with bone 
metastasis at initial 
presentation 
Polymerase chain reaction-
restriction fragment length 
polymorphism or automated 
sequencer with genotyping 
Kaplan-Meier curve, 
log rank test and cox 
proportional hazards 
model 
CA repeat polymorphism, rs12423791 and rs6220 are 
associated with cancer-specific survival (p=0.013, 0.014 
and 0.014, respectively).  
Haplotype in LD block 3 was significantly associated with 
cancer–specific survival (p=0.0003).  
Patients with all the risk factors (19-repeat allele, C allele of 
rs12423791, or C-T haplotype) had a significantly shorter 
cancer specific survival than those with 0-2 of the risk 
factors (p=0.0003).  
Johansson  2007 To investigate what extent 
genetic variation in the 
IGF-I gene is related to 
prostate cancer risk 
Men with PCa (n=2863) 
Controls: men randomly 
selected from the Swedish 
population (n=1737)  
Genotyping by 5’ nuclease 
assay  
Likelihood-ratio test 
and permutation 
testing  
 
Common haplotypes in the block covering the 3
’
region of 
the IGF1 gene showed significant global association with 
prostate cancer risk (p = 0.004), with TCC haplotype giving 
an odds ratio of 1.46 (95% CI 5 1.15–1.84, p = 0.002). 
 
 
Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGF-I (Continued) 
Chang  2013 To investigate the 
association of 4 common 
SNPs in IGF-I and IGF-IR 
with age, PSA, Gleason 
score, surgical margin, 
lymph node metastasis and 
PSA recurrence  
320 localised prostate 
cancer patients receiving 
radical prostatectomy 
Genomic DNA was extracted 
from peripheral blood of 
patients.  
Genotyping (Sequenom 
iPLEX MALDI-TOF mass 
spectrometry  
Logistic regression 
analyses and Cox 
proportional hazards 
regression: 
association of 
individual SNP 
alleles, genotypes 
and haplotypes with 
clinic pathological 
characteristics  
 
Multi-factor 
dimensionality 
reduction (MDR) 
analysis: interaction 
between SNPs and 
PSA recurrence.  
 
IGF-I rs2946834 alleles/genotypes and an IGF-I specific 
haplotype AT, containing the minor allele of rs2946834, were 
associated with higher risk of having advanced-stage 
prostate cancer (OR: 1.58; 95 % CI: 1.05–2.38; p= 0.027). 
IGF-I haplotype AT was associated with an increased risk of 
having positive surgical margin after RP (OR, 1.65; 95 % 
CI:1.06–2.58; p= 0.03). 
 
IGF-II 
Lai 2005 Investigate whether 
polymorphism of IGF-II 
could be used as a genetic 
marker for risk of PCa.  
Patients with PCa (n=96); 
Controls: Healthy male 
volunteers from the same 
geographic area (n=121).  
PCR using primers for IGF-II 
gene exon 9 
Chi-square test No significant difference between distribution of IGF-II gene 
C/T polymorphism between the healthy control group and 
the patients with PCa (p=0.78).  
No significant difference in the distribution of the IGF-II gene 
C/T polymorphism between individuals younger than 70yrs 
and those older than 71yrs (p=0.5).  
 
Hu  2006 To determine whether the 
M6P/IGF-IIR gene is 
inactivated in PCa.   
 
43 patients with PCa 
treated with radical 
prostatectomy  
Regions of tumour, normal 
prostate and PIN were 
identified and cells were 
excised by laser capture 
microdissection.  
DNA segments amplified with 
PCR 
Pearson chi-squared 
test and ANOVA: 
difference between 
groups 
Kaplan-Meier curve: 
disease-free survival 
M6P/IGF-IIR gene was polymorphic in 83.7% (36/43) of 
patients.  
41.7% (15/36) of these informative patients had loss of 
heterozygosity (LOH) in the tumor tissue. 11/15 patients with 
LOH in malignant tissue also had HG-PIN. Of these 63.6% 
(7/11) also had LOH in HG-PIN tissue.  
There was no significant difference in age, PSA levels, 
stage, Gleason score, proliferative index, cancer 
involvement, lymphatic/vascular invasion and perineural 
invasion between the groups with or without LOH.  
No significant difference in disease-free survival between the 
groups of with or without LOH. 
 
 
Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGF-II (Continued) 
Lui 2006 To explore the genomic 
imprinting of IGF-II in PCa 
and its correlation to 
disease progression.  
PCa (n=41), BPH (n=27) 
and normal prostate tissue 
(n=13)  
PCR-RFLP Fisher’s exact test; t-
test; Kaplan-Meier 
and log rank test 
Rates of heterozygote of IGF-II DNA were 70.7% in PCa, 
55.5% in BPH and 61.5% in normal prostate tissue group.  
Occurrence rate of LOI of IGF-II was higher in PCa than in 
BPH and normal tissue (p=0.05).  
LOI of IGF-II had no correlation to age, PSA, presence of 
bone metastasis, and cell differentiation before 
endocrinotherapy.  
After androgen blockade, the 1 year progression free 
survival rate was lower in patient s with LOI of IGF-II tan in 
patients without LOI of IGF-I (p=0.04).  
Fu 2008 Determined whether 
normal imprint is altered 
for the IGF-2 gene with 
aging in the prostate.  
Prostate tissues from 
C57/B6 mice (containing a 
Cast IGF-2-H19 allele)  
Histologically normal 
human prostate 
specimens from men 
without cancer (n=40) or 
men with cancer (n=25).   
qPCR, DNA methylation 
sequencing, ChIP 
Not stated Significant loss of imprinting (LOI) for IGF-2 in the 
dorsolateral prostate (DLP) beginning at 11 months 
compared to young sexually mature mice (3 months).  LOI 
is associated with increase in IGF-2 mRNA and protein 
expression.  
siRNA mediated down-regulation of CTCF induced LOI in 
prostate cells.  
No alteration in LOI of IGF-2 in the ventral prostate or non 
prostate tissues.  
LOI in histologically normal prostate tissues from men with 
cancer is significantly greater than men without cancer 
(p=0. 02).   
Paradowska 
 
2009 Analysed DNA methylation 
and histone modifications 
in the differentially 
methylated region (DMR) 
of IGF-II/H19 in benign 
prostate hyperplasia (BPH) 
and prostate carcinoma 
(PCa). 
 
30 prostate radical 
prostatectomy or 
cystoprostatectomy 
Control: 17 BPH 
surrounding tumors 
 
Sodium bisulfite treatment 
and DNA sequencing of 
genomic DNA 
The methylation pattern of 
17 CpGs within 227 bp of 
the H19 fragment was 
characterized from each 
DNA sample. 
 ChIP 
Mann-Whitney test All BPH samples demonstrated >80% methylation of CpGs 
while 41% of CpGs were methylated in 9 out of 30 PCa 
specimens. Statistically significant differences in the 
methylation state was found between PCa and BPH 
groups, especially in the differentially methylated region 
(DMR) of H19 (p<0.0001) and in the imprinting control 
region (ICR) (p=0.0034), which corresponds to CTCF 
binding domain. 
ChIP assay revealed that dimethyl H3K9 is associated with 
the ICR of IGF-II/H19 in BPH, but not in PCa (p<0.0001). 
 
 
Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGF-II (Continued) 
Bhusari 2011 To define whether IGF-2 
LOI in histologically normal 
prostate tissues in 
relationship to tumour foci 
and gene expression 
Prostatectomy samples 
containing tumour and 
associated normal tissue 
(n=18) 
Controls: Normal prostate 
samples without any 
associated tumours from 
age-matched men.  
 
Fluorescent primer 
extension (FluPE), qPCR, 
DNA methylation analysis  
Spearman’s 
correlation; two-
tailed t-test 
Marked IGF-2 LOI in adjacent tumour associated tissues 
(39 ±3.1%) but not in tissues distant (38 ±5.3%)  from 
tumour foci (45±2.9%).  
IGF-2 imprinting correlated with IGF-2 expression in 
adjacent tumour associated tissues but not within the 
tumour foci.  
Hypomethylation of IGF-2 DMRO region correlated with 
decreased IGF-2 expression in tumours (p<0.01).  
The expression of IGF-2 and H19 gene were increased in 
adjacent and distant tissues compared to tumours 
(p<0.05).  
Belharazem  2012 To investigate levels of 
IGF-II protein levels and 
IGF-II 820G/A genotype 
whether loss of imprinting 
(LOI) of IGF-II in normal 
circulating peripheral blood 
lymphocytes can predict 
increased PCa risk 
113 blood samples of 
patients with a history of 
radical prostatectomy for 
PCa  
Controls: volunteer blood 
donors  
ELISA: serum IGF-II and 
IGFBP-3 levels 
Restriction-fragment length 
polymorphism: 
heterozygosity at ApaI-
sensitive 820G>A locus on 
exon 7 of IGF-II gene  
LOI or retention of imprinting 
(ROI): cDNA amplification 
from heterozygous cases by 
a nested RT-PCR method. 
Bisulfite-DNA sequencing: 
Methylation status of IGF-II 
imprinting control region 
(ICR) 
Chi-square test, 
Mann–Whitney U 
test and Spearman’s 
test 
Among men with a history of PCa, the 820G/A genotype 
was significantly more frequent than among healthy control 
persons (50.5% in PCa patients vs 43% in controls; OR 
1.92; 95% CI: 1.22–3.02, p=0.005).  
LOI in PCa patients was significantly more frequent (16/41 
cases (39%), P=0.03).  
Higher degree of methylation in samples with LOI than in 
ROI in both PCa patients and controls.  
All ICRs in samples of RPE patients, irrespective of the 
imprinting status, showed a higher degree of methylation 
compared with control samples.  
 
 
 
 
 
 
Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGFBP-2 
Hu  2006 To determine whether the 
M6P/IGF-IIR gene is 
inactivated in PCa.   
 
43 patients with PCa 
treated with radical 
prostatectomy  
Regions of tumour, normal 
prostate and PIN were 
identified and cells were 
excised by laser capture 
microdissection.  
DNA segments amplified 
with PCR 
Pearson chi-squared 
test and ANOVA: 
difference between 
groups 
Kaplan-Meier curve: 
disease-free survival 
M6P/IGF-IIR gene was polymorphic in 83.7% (36/43) of 
patients.  
41.7% (15/36) of these informative patients had loss of 
heterozygosity (LOH) in the tumor tissue. 11/15 patients 
with LOH in malignant tissue also had HG-PIN. Of these 
63.6% (7/11) also had LOH in HG-PIN tissue.  
No significant difference in age, PSA levels, stage, 
Gleason score, proliferative index, lymphatic/vascular 
invasion, and disease-free survival between the groups 
with or without LOH.  
Paradowska 
 
2009 Analysed DNA methylation 
and histone modifications 
in the differentially 
methylated region (DMR) 
of IGF-II/H19 in benign 
prostate hyperplasia (BPH) 
and prostate carcinoma 
(PCa). 
 
30 prostate radical 
prostatectomy or 
cystoprostatectomy 
Control: 17 BPH 
surrounding tumors 
 
Sodium bisulfite treatment 
and DNA sequencing of 
genomic DNA 
The methylation pattern of 
17 CpGs within 227 bp of 
the H19 fragment was 
characterized from each 
DNA sample. 
 ChIP 
Mann-Whitney test All BPH samples demonstrated >80% methylation of CpGs 
while 41% of CpGs were methylated in 9 out of 30 PCa 
specimens. Statistically significant differences in the 
methylation state was found between PCa and BPH 
groups, especially in the differentially methylated region 
(DMR) of H19 (p<0.0001) and in the imprinting control 
region (ICR) (p=0.0034), which corresponds to CTCF 
binding domain. 
ChIP assay revealed that dimethyl H3K9 is associated with 
the ICR of IGF-II/H19 in BPH, but not in PCa (p<0.0001). 
IGFBP-3 
Okugi  2006 Investigated whether the 
methylation status of 
IGFBP-3 promoter in 
prostate tissues influences 
the progression and 
prognosis of prostate 
cancer. 
PCa patients (n=38)  
Controls: BPH (n=57) 
 
Bisulfite modification and 
methylation-specific PCR of 
genomic DNA 
Hep-methylation status and 
NSCLC-methylation status 
 
Chi-squared test: 
distribution of 
methylation 
frequency of IGFBP-
3 promoter region 
 
Unconditional 
logistic regression: 
OR and 95% CI 
No significant difference in the methylation frequency of 
the IGFBP-3 promoter between cases and controls 
(OR:1.53; 95% CI: 0.85-5.56; p=0.15) for Hep-primer 
method; OR=3.24; 95% CI: 0.46-15.42; p=0.21 for 
NSCLC-primer method).  
No statistically significant association between the 
hypermethylation of IGFBP-3 promoter and clinical stage 
or Gleason score.  
 
 
 
 
 
Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGFBP-3 (Continued) 
Perry  2007 Investigated the 
methylation pattern of 
IGFBP-3 in benign, pre-
invasive and cancerous 
prostate tissues 
40 prostatectomy 
specimens; 39 primary 
tumours (USA); 14 HG-
PIN lesions (from 79 
patients) with PCa.  
Control: histologically 
normal adjacent tissue 
from PCa patients and 
BPH lesions  
Bisulfite modification of 
genomic DNA  and 
quantitative methylation 
specific PCR 
 
Fisher’s exact test 
 
Kruskal-Wallis one 
way ANOVA test 
and Wilcoxon-
matched pairs test  
IGFBP3 promoter was completely unmethylated in the 
histologically normal prostate samples.  
In the BPH samples, the frequencies of IGFBP-3 promoter 
methylation were significantly less than detected in 
tumours (P<0.0001). 
IGFBP-3 promoter methylation was only detected in 
HGPIN samples from patients whose adjacent tumour was 
also methylated The frequency of IGFBP3 methylation in 
HGPIN was not statistically different from tumour 
(p=0.383). 
Methylation of IGFBP-3 promoter was detected in 
significantly more in tumours with Gleason score ≥7, than 
≤6 (p=0.01), but was not significantly correlated with TNM 
classification or PSA level. 
Johansson  2009 Analysed genetic variation 
within genes coding for 
IGFBP in relation to 
prostate cancer incidence 
and survival.  
 
Genotyping analysis: PCa 
cases (n=2774); Controls: 
men randomly selected 
from the Swedish 
population (n=1736) 
 
Genotyping by 5’ nuclease 
assay  
ELISA: plasma total and 
intact IGFBP-3 levels 
Conditional logistic 
regression: odds 
ratio 
Cox proportional 
hazards: survival 
analysis  
Likelihood ratio test 
No association between the IGFBP-3 genetic variants and 
prostate cancer incidence or survival.  
The rare allele of the IGFBP-3 SNP rs2854744 was 
associated with elevated plasma levels of total IGFBP-3 
(Ptrend =9x 10
-8), but not intact IGFBP3 (Ptrend=0.16).  
 
Note: PCa: Prostate cancer; HG-PIN: High grade prostatic intraepithelial neoplasia; IHC: immunohistochemistry; NAP: normal adjacent counterpart; SEM: standard error of mean; qPCR: quantitative 
reverse-transcription polymerase chain reaction; BPH: Benign prostatic hyperplasia; ChIP: Chromatin immunoprecipitation; ab: antibody; ELISA: enzyme-linked immunosorbent assay; PSA: prostate 
specific antigen; TURP: transurethral resection of the prostate; MALDI-TOF: matrix-assisted laser desorption/ionization-time of flight; PCR: polymerase chain reaction; DRE: digital rectal 
examination; OR: Odds ratio; CI: confidence interval ; PCR-RFLP: Polymerase chain reaction-based restrictive fragment length polymorphism  
  
Supplementary Table 5: Studies investigating circulating levels of IGF system and prostate cancer included as supporting evidence.  
Study  Year Experiments Samples Experimental 
procedures 
Statistical analysis  Results 
IGF-I 
Tricoli  1999 To determine the overall plasma 
levels of IGF-I in men at higher 
risk of PCa development and to 
investigate the relationships 
between demographic and IGF-I 
levels  
105 men ( 63 African American (AA) 
and 42 White) with no personal history 
of PCa but have at least one 1st degree 
relative diagnosed with PCa. 
ELISA Wilcoxon test; 
Spearman 
correlation 
coefficient; linear 
regression;  
Mean plasma level of IGF-I was not 
significantly different between AA (162.3ng/ml) 
and white (172.1ng/ml) men (p=0.42).  
Inverse relationship between IGF-I plasma 
levels and age (p=0.008).  
Baffa  2000 Relation between serum IGF-I 
and PCa 
57 patients who underwent radical 
prostatectomy for adenocarcinoma. 
Serum samples collected before radical 
prostatectomy (T0) or 6 months after 
radical prostatectomy (T6) 
Controls: 39 age-matched controls  
Active IGF-I Elisa Kit  
(Diagnostic systems Lab)  
Welch’s t-test and 
paired t-test  
Serum IGF-I levels were lower in patients with 
PCa (124.6± 58.2ng/ml) compared to the 
control (157.5± 70.8ng/ml)  (p=0.0192).  
Mean serum IGF-I levels for case patients at 
T0 (124.91± 58.6ng/ml) was lower than 
patients in the T6 group (148.49± 57.2ng/ml)  
(p=0.0056).  
Shariat  2000 Investigate pre-operative levels 
of IGF-I plasma levels in 
patients with clinically localize 
PCa 
120 patients who underwent radical 
prostatectomy for clinically localized 
prostatic adenocarcinoma.  
Control: Healthy patients without PCa 
(n=20). (No prior history of any cancer 
or chronic disease, a normal digital 
rectal examination, and a PSA<2ng/ml).  
DSL-105600 Active-IGF-I 
ELISA assay 
 
ANOVA: means 
among patient 
groups.  
 
Spearman’s rank 
correlation 
coefficient: compare 
ordinal and 
continuous variables 
 
Logistic regression 
multivariate analysis 
of binary outcomes.  
From univariate analysis, pretreatment IGF-I 
levels did not correlate with age (p=0.89), 
preoperative PSA (p=0.28), pathologic 
Gleason score (p=0.49) and pathologic stage 
(p=0.56).  
In both a univariate and a multivariate logistic 
regression analysis that included preoperative 
IGF-I, preoperative PSA, clinical stage, and 
biopsy Gleason score, IGF-I levels did not 
predict organ- confined disease (P =0.56, P = 
0.4165, respectively).  
Shariat 
(Cont.) 
    Kaplan-Meier 
Curves: Survival 
analysis 
 
Cox Proportional 
hazards: time to 
recurrence  
 
No significant difference for PSA progression-
free survival between patients with high IGF-I 
levels (≥151.1ng/ml) and patients with low 
IGF-I levels (<151.1ng/ml) (P= 0.76).  
IGF-I levels in radical prostatectomy patients 
were not significantly higher than those in 
healthy subjects or in patients with metastatic 
disease (p=084). 
Stattin  2001 To investigate if increased 
plasma leptin levels are 
associated with development of 
PCa.  
PCa Patients (n=149); Controls: 
Matched men without cancer (n=298)  
Immunoradiometric assays Pearson correlation 
analysis; Univariate 
and multivariate 
logistic regression 
analysis 
Adjustments for IGF-I or IGFBP 1-3, (either as 
continuous or categorical variables) in 
separate and combined multivariate models 
did not attenuate the increased risk associated 
with moderately elevated leptin levels.  
Study  Year Experiments Samples Experimental 
procedures 
Statistical analysis  Results 
IGF-I (Continued) 
Yu  2001 To determine changes in IGF-I, 
IGFBP-2 and IGFBP-3 levels in 
serial post-operative serum 
samples from PCa patients with 
and without relapse 
PCa Patients (n=148) 
Patients who developed recurrence 
(n=38) 
Controls: patients who remained in 
remission (n=40) 
ELISA to measure IGF-I, 
IGFBP-2 and IGFBP-3 in 
serum samples 
Wilcoxon rank-sum 
test; Friedman test; 
Page’s L test; 
generalized linear 
model (GLM) 
No difference in IGF-I levels between cases 
and controls (p=0.28).  
 
Latif  2002 To assess the relationships 
between IGF-I and PCa disease 
stage 
 
Patients with BPH (n=17), stage T1/T2 
PCa (n=15), T3/T4 cancer (n=16) and 
metastatic PCa (n=12) 
Immuno-enzymometric 
assay: IGF-I  
 
ELISA: IGFBP-3  
 
Anova (Kruskal-
Wallis) and Mann-
Whitney U-test 
IGF-I concentrations were similar between 
patients with BPH and those with cancer.  
No correlation between age and IGF-I 
concentration.  
Oliver  2003 Assess whether serum levels of 
IGFs and IGFBPs were 
associated with grade, serum 
PSA and clinical stage. 
 
224 men (50-70yrs) with screen-
detected prostate cancer identified via 
population-based case-finding in three 
UK centres 
All had total PSA ≥3ng/ml 
No healthy controls 
 
 
IGF-I & -II (ELISA, DSL)  
IGFBP-2 (RIA, DSL),  
IGFBP-3 (RIA, 'in-house' 
assay) 
the molar ratio of IGF-
I:IGFBP-3 (a measure of 
IGF-I bioavailability) was 
derived. 
Not stated Geometric mean levels of IGF-I did not vary by 
stage or grade but were higher in cases with a 
higher PSA (PSA 3-5ng/ml geometric mean 
(CI) IGF-I 126.5ng/ml (121.5-133.0), PSA 
20+ng/m1 IGF-I 144.0 (129.0- 159.2), 
Ptrend=0.05). 
The IGF-I:IGFBP-3 molar ratio did not differ by 
clinical stage, but was significantly higher in 
cases with higher PSA (PSA 3-5ng/ml 
geometric mean (CI) molar ratio 19.8% (18.6-
21.0), PSA 20+ng/ml molar ratio 23.2% (20.6-
26.4), Ptrend=0.03) 
The IGF-I:IGFBP-3 molar ratio was higher in 
men with higher grade tumours, (Gleason <7 
geometric mean (CI) molar ratio 19.8% (18.8-
21.0), Gleason 2:7 geometric mean (CI) molar 
ratio 22.3% (20.4-24.2), P=0.03) 
Woodson  
 
2003 To evaluate the association 
between pre-diagnostic levels of 
IGF-I and IGFBP-3 and PCa 
risk in a nested case-control 
study (RAS) 
To examine changes in serum 
IGF-I and IGFBP-3 levels over 
time (SSS) 
 
RAS:  PCa (n=100); Controls: randomly 
selected members from cohort  
SSS: PCa (n=21);          Controls:  trial 
participants who had no cancer 
diagnosed (except non-melanoma skin 
cancer) over the full period of study 
follow-up and had two serum draws at 
least 1 year apart.  
ELISA Logistic regression 
and paired t-test 
No significant association between prostate 
cancer risk and either serum IGF-I (OR: 0.52; 
95% CI, 0.23–1.16) after adjusting for age, 
BMI, intervention group assignment.  
Ratio of IGF-I: IGFBP-3 had borderline 
significant inverse association with PCa risk 
(p=0.06).  
The cases had an average 18% increase in 
serum IGF-I levels compared with a 4% 
decrease among controls (P=0.02). 
 Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGF-I (Continued) 
Tu  2004 To investigate the levels of 
IGF-1 and IGFBP-3 in bone 
marrow aspirates and plasma 
samples of men with 
advanced prostate cancer 
42 patients with widespread bone 
metastases (n-22) and without bone 
metastasis (n=20) 
 
ELISA Not stated Levels of IGF-I and IGFBP-3 were lower in 
bone marrow supernatant than in plasma.  
Bone marrow supernatant: median IGFBP-3 
levels were significantly lower in the Met group 
(834.5ng/ml) than in the Non-Met group 
(1650ng/ml) (p=0.0001).  
No correlation between IGF-I levels and 
metastasis.  
Nam  2005 To determine whether high 
serum IGF-I levels are 
associated with precancerous 
lesions of the prostate 
To compare serum IGF-I and 
IGFBP-3 levels between men 
with PCa and those without 
cancer or with HG-PIN 
Cases: Patients with HGPIN from 
prostate biopsy.  
Controls: no evidence of 
adenocarcinoma of the prostate or HG-
PIN ( 2 or more negative biopsies) 
ELISA Not stated The mean serum IGF-I level for patients with 
HGPIN (130.2 ng/mL) was significantly higher 
than for controls (118.8 ng/mL, P = 0.01).  
The crude odds ratio for having HGPIN for 
patients with the highest quartile of serum IGF-
I level compared with the lowest quartile group 
was 1.95 [95% confidence interval (CI), 1.0-
3.7; P = 0.04) 
The mean IGF-I level for patients with cancer 
was 119.4 ng/mL (n = 483) and was not 
significantly different from the 205 patients in 
the control group (118.8 ng/mL, P = 0.85). 
Woongeol  2007 Case-control study to 
investigate the association 
between serum IGF-I and 
IGFBP-3 levels and prostate 
cancer risk 
330 men (165 cases treated by radical 
prostatectomy and 165 healthy age-
matched controls).  
Not stated  Conditional logistic 
regression  
Risk of PCa not related to IGF-I and IGF-
1:IGFBP-3 molar ratio.  
Ito  2009 IGF-1 and IGFBP-3 kinetics  78 cases with baseline PSA<4ng/ml 
and diagnosed with PCa after 
undergoing at 3 times of screening 
 
Control: 156 age-adjusted and 
baseline PSA-adjusted men without 
prostate cancer and screened at least 
3 times. Men with PSA velocity 
<0.2ng/ml/yr was recommended for 
selection.  
 
Serum IGF-1 and IGFBP-3 
were measured using serum 
samples at initial, 
intermediate and last 
screening visits in each 
participant. 
 
Not stated There was no significant difference in the 
baseline IGF- 1, baseline IGFBP-3, IGF-1 
velocity and IGFBP-3 velocity between the 
case and the control group. 
 
 
 
Study  Year Experiments Samples Experimental procedures Statistical analysis  Results 
IGF-I (Continued) 
Mucci  2010 To investigate the levels of 
IGF-I and IGFBP-3 in 
plasma samples from PCa 
patients  
545 incident cases; Controls: 545 
matched-controls 
ELISA  Conditional logistic 
regression models 
No association between free IGF-I and 
prostate cancer risk (RR, 0.9; 95% CI: 0.6-1.3) 
Rowlands  2012 Investigated associations 
of circulating IGF-I, IGF-II, 
IGFBP-2 and IGFBP-3 with 
all-cause and PCa mortality 
in men with clinically 
identified PCa, stratified by 
whether localised (stage T1 
or T2) or advanced (T3, T4, 
N1 or M1) at diagnosis. 
396 men with PCa 
 
In-house radioimmunoassay 
(RIA): For IGF-I, IGF-II and 
IGFBP-3 
ELISA: total IGF-I, IGF-II or 
IGFBP-3  
 
Age-adjusted linear 
regression models, 
likelihood ratio test 
and Cox regression 
hazards regression 
 
In men with advanced cancer, IGF-I was 
positively associated (HR 1.20; 95% CI: 0.96, 
1.49; p = 0.11) and IGFBP-3 was inversely 
associated (HR 0.84; 95% CI: 0.70, 1.01; p = 
0.07) with all-cause mortality after controlling 
for age, treatment status, smoking, prostate-
specific antigen and Gleason grade at 
diagnosis. 
IGF-I was positively associated with prostate 
cancer mortality in advanced cases (HR 1.23; 
95% CI: 0.94, 1.62; p = 0.13). 
In advanced cancers, associations of IGF-I 
with all-cause (HR 1.68; 95% CI: 1.28, 2.23; 
p<0.001) and prostate cancer–specific (HR 
1.59; 95% CI: 1.11, 2.28; p = 0.01) mortality 
strengthened (and were conventionally 
statistically significant) and controlling for 
IGFBP-3.  
IGF-II  
Oliver  2003 Assess whether serum 
levels of IGFs and IGFBPs 
were associated with 
grade, serum PSA and 
clinical stage. 
 
224 men (50-70yrs) with screen-
detected prostate cancer identified via 
population-based case-finding in three 
UK centres. All had total PSA ≥3ng/ml 
No healthy controls 
IGF-I & -II (ELISA, DSL); 
IGFBP-2 (RIA, DSL); IGFBP-3 
(RIA, 'in-house' assay) 
Molar ratio of IGF-I:IGFBP-3 
(a measure of IGF-I 
bioavailability) was derived. 
Not stated After adjustment for age and centre, geometric 
mean levels of IGF-II did not differ by disease 
stage, grade or PSA. 
 
Belharazem  2012 To investigate levels of 
IGF-II protein levels and 
IGF-II 820G/A genotype 
whether loss of imprinting 
(LOI) of IGF-II in normal 
circulating peripheral blood 
lymphocytes can predict 
increased PCa risk 
113 blood samples of patients with a 
history of radical prostatectomy for 
PCa  
Controls: volunteer blood donors  
 
ELISA: serum IGF-II and 
IGFBP-3 levels 
Chi-square test, 
Mann–Whitney U 
test and Spearman’s 
test 
 
In contrast to controls, IGF-II levels in all PCa 
patients were increased and appeared 
uncoupled from the imprinting status (p=0.9).  
IGF-II protein levels both in patients and in 
controls were tightly correlated with IGFBP-3 
levels (r=0.8; p<0.0001).  
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IGFBP-2 
Yu  2001 To determine changes in 
IGF-I, IGFBP-2 and IGFBP-
3 levels in serial post-
operative serum samples 
from PCa patients with and 
without relapse 
PCa Patients (n=148) 
Patients who developed recurrence 
(n=38) 
Controls: patients who remained in 
remission (n=40) 
ELISA to measure IGF-I, 
IGFBP-2 and IGFBP-3 in serum 
samples 
Wilcoxon rank-sum 
test; Friedman test; 
Page’s L test; 
generalized linear 
model (GLM) 
Lower serum levels of IGFBP-2 in cases than in 
controls (p<0.05).  
In sequential samples, IGFBP-2 levels 
increased over time in controls (p=0.014) but 
not in cases (p=0.53).  
Oliver  2003 Assess whether serum 
levels of IGFs and IGFBPs 
were associated with grade, 
serum PSA and clinical 
stage. 
 
224 men (50-70yrs) with screen-
detected prostate cancer identified via 
population-based case-finding in three 
UK centres. All had total PSA ≥3ng/ml 
No healthy controls.  
IGF-I & -II (ELISA, DSL); 
IGFBP-2 (RIA, DSL); IGFBP-3 
(RIA, 'in-house' assay) 
Molar ratio of IGF-I:IGFBP-3 (a 
measure of IGF-I bioavailability) 
was derived.  
Not stated After adjustment for age and centre, geometric 
mean levels of IGFBP-2 did not differ by disease 
stage, grade or PSA.  
IGFBP-3 
Smith 1999 Compared concentrations of 
IGFBP-3 and PSA in bone 
metastases and measured 
serum IGFBP-3 in patients 
with changing PSA 
concentrations.  
Metastatic bone tissues from patients 
with PCa (n=6) and patients with breast 
cancer (n=5)  
Western blot: IGFBP-3 
concentrations in metastatic 
tissue  
ELISA: serum IGFBP-3 levels 
Mann-Whitney test  IGFBP-3 tissue concentrations in PSA-positive 
bone metastases from patients with PCa were 
lower compared to PSA-negative bone 
metastases from patients with breast cancer 
(p=0.0081).  
Inverse correlation between serum PSA and 
IGFBP-3 concentrations in patients with PCa 
during period of therapeutic response or disease 
progression.  
Tricoli  1999 To determine the overall 
plasma levels of IGF-I in 
men at higher risk of PCa 
development and to 
investigate the relationships 
between demographic and 
IGF-I levels  
105 men ( 63 African American (AA) 
and 42 White) with no personal history 
of PCa but have at least one 1st degree 
relative diagnosed with PCa. 
ELISA Wilcoxon test; 
Spearman correlation 
coefficient; linear 
regression;  
Mean plasma level of IGFBP-3 was lower in AA 
(2789 ng/ml) than in white (3216ng/ml) men 
(p=0.005).  
No correlation between IGFBP-3 plasma levels 
and age.   
Yu  2001 To determine changes in 
IGF-I, IGFBP-2 and IGFBP-
3 levels in serial post-
operative serum samples 
from PCa patients with and 
without relapse 
PCa Patients (n=148) 
Patients who developed recurrence 
(n=38) 
Controls: patients who remained in 
remission (n=40) 
ELISA to measure IGF-I, 
IGFBP-2 and IGFBP-3 in serum 
samples 
Wilcoxon rank-sum 
test; Friedman test; 
Page’s L test; 
generalized linear 
model (GLM) 
Lower serum levels of IGFBP-3 in cases than in 
controls (p<0.05).  
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IGFBP-3 (Continued) 
Latif  2002 To assess the relationships 
between IGF-I and PCa 
disease stage 
Patients with BPH (n=17), stage T1/T2 
PCa (n=15), T3/T4 cancer (n=16) and 
metastatic PCa (n=12) 
Immuno-enzymometric assay: 
IGF-I  
 
ELISA: IGFBP-3  
Anova (Kruskal-
Wallis) and Mann-
Whitney U-test 
IGFBP-3 concentrations were similar between 
patients with BPH and those with cancer.  
Age was correlated with IGFBP-3 
concentrations (r=-0.4; p=0.008).   
Oliver  2003 Assess whether serum 
levels of IGFs and IGFBPs 
were associated with grade, 
serum PSA and clinical 
stage. 
 
224 men (50-70yrs) with screen-
detected prostate cancer identified via 
population-based case-finding in three 
UK centres. All had total PSA ≥3ng/ml 
No healthy controls 
IGF-I & -II (ELISA, DSL); 
IGFBP-2 (RIA, DSL); IGFBP-3 
(RIA, 'in-house' assay);  
Molar ratio of IGF-I:IGFBP-3 (a 
measure of IGF-I 
bioavailability) was derived. 
Not stated After adjustment for age and centre, geometric 
mean levels of IGFBP-3 did not differ by 
disease stage, grade or PSA. 
 
Tu  2004 To investigate the levels of 
IGF-1 and IGFBP-3 in bone 
marrow aspirates and 
plasma samples of men 
with advanced prostate 
cancer.  
42 patients with widespread bone 
metastases (n-22) and without bone 
metastasis (n=20) 
ELISA Not stated IGFBP-3 levels in the bone marrow 
supernatant inversely correlated with serum 
alkaline phosphatase (p=0.0003) and PSA 
(p=0.02).  
Nam  2005 To determine whether high 
serum IGF-I levels are 
associated with 
precancerous lesions of the 
prostate 
To compare serum IGF-I 
and IGFBP-3 levels 
between men with PCa and 
those without cancer or with 
HG-PIN 
Cases: Patients with HGPIN from 
prostate biopsy.  
Controls: no evidence of 
adenocarcinoma of the prostate or HG-
PIN ( 2 or more negative biopsies) 
ELISA Not stated The mean IGFBP-3 level was slightly higher for 
patients with HGPIN (2,393.9 ng/mL) 
compared with controls (2,276.0, P = 0.06).  
The crude odds ratio for having HGPIN for 
patients with the highest quartile of serum 
IGFBP-3 level compared with the lowest 
quartile group was 2.04 (95% CI, 1.1- 3.9; P = 
0.03).  
The mean IGFBP-3 level for patients with 
cancer (2,222.7 ng/mL) was also not 
significantly different to the control group 
(2,276.0 ng/mL, P = 0.26).  
Woongeol  2007 Case-control study to 
investigate the association 
between serum IGF-I and 
IGFBP-3 levels and 
prostate cancer risk 
330 men (165 cases treated by radical 
prostatectomy and 165 healthy age-
matched controls).  
Not stated  Conditional logistic 
regression  
Strong inverse association between IGFBP-3 
and PCa risk.  
Men in highest quartile of IGFBP-3 had 88% 
reduced risk of PCa compared with men in the 
lowest quartile (OR=0.12; 95% CI: 0.05-0.64; 
p<0.01).  
48% and 76% reduced risk of aggressive 
prostate cancer in 3rd and 4th quartile of IGFBP-
3 levels compared to 1st quartile. 
Note: PCa: Prostate cancer; HG-PIN: High grade prostatic intraepithelial neoplasia; IHC: immunohistochemistry; NAP: normal adjacent counterpart; SEM: standard error of mean; qPCR: quantitative 
reverse-transcription polymerase chain reaction; BPH: Benign prostatic hyperplasia; ChIP: Chromatin immunoprecipitation; ab: antibody; ELISA: enzyme-linked immunosorbent assay; PSA: prostate 
specific antigen; TURP: transurethral resection of the prostate; MALDI-TOF: matrix-assisted laser desorption/ionization-time of flight; PCR: polymerase chain reaction; DRE: digital rectal 
examination; OR: Odds ratio; CI: confidence interval  
Supplementary Table 6 - GRADE assessment of studies of milk and IGF-I levels 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 4 human RCTs, 1 intervention 
study and 24 observational 
studies 
2 Larger number of observational studies with a small number of 
RCTs, therefore start with score of 2 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Most studies are moderate or unclear RoB 
Inconsistency Not serious 0 Just one outlier, but can be explained due to outcome being 
measured 65 years after exposure 
Indirectness Not serious 0 All studies looked at the effect of milk/dairy products on IGF1 levels 
Imprecision Not serious 0 Many large studies 
Publication bias Serious -1 Although not clearly evident there is likely to be publication bias in 
this area of research 
Factors increasing confidence 
Strength of association Substantial +1 Combined p-value is very low. 
Dose-response  0 Studies were not able to examine this robustly (RCTs based on a 
single dose/intervention, or food frequency questionnaires) 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 2 
Statement of quality of evidence There is currently a low level of evidence linking milk with IGF-I levels and this suggests 
a positive association. 
 
  
Supplementary Table 7 - GRADE assessment of studies of milk and IGF-II levels 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 3 observational studies 2 Only 3 studies all observational, although large population sizes 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 1 low, 2 unclear 
Inconsistency Not serious 0 Difficult to determine due to the small number of studies, but no 
strong evidence of inconsistency 
Indirectness Not serious 0 All studies looked at the effect of milk/dairy products on IGFII levels 
Imprecision Serious -1 Based on just 3 studies, two of which had wide confidence intervals 
Publication bias Serious -1 Although not clearly evident there is likely to be publication bias in 
this area of research 
Factors increasing confidence 
Strength of association  0 Strong association but this was in just one study 
Dose-response  0 Not robust 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence linking milk with IGF-II levels and this 
suggests a positive association. 
 
  
Supplementary Table 8 - GRADE assessment of studies of milk and IGFBP-I levels  
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 2 observational studies 2 Only 2 studies both observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 1 low, 1 unclear 
Inconsistency Not serious 0 Difficult to determine due to the small number of studies, but no 
strong evidence of inconsistency 
Indirectness Not serious 0 Both studies looked at the effect of milk/dairy products on IGFBP-I 
levels 
Imprecision Serious -1 Based on just 2 studies 
Publication bias Serious -1 Although not clearly evident there is likely to be publication bias in 
this area of research 
Factors increasing confidence 
Strength of association  0 No evidence of an association in either study 
Dose-response  0 No evidence of a dose response 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence linking milk with IGFBP-1 levels and this 
suggests no association. 
 
  
Supplementary Table 9 – GRADE assessment of studies of milk and IGFBP-2 levels 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 3 observational studies 2 Only 3 studies all observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 2 low, 1 unclear 
Inconsistency Not serious 0 Difficult to determine due to the small number of studies, but no 
strong evidence of inconsistency 
Indirectness Not serious 0 Both studies looked at the effect of milk/dairy products on IGFBP-2 
levels 
Imprecision Serious -1 Based on just 3 studies 
Publication bias Serious -1 Although not clearly evident there is likely to be publication bias in 
this area of research 
Factors increasing confidence 
Strength of association  0 Some evidence of a negative association in 2 studies but no 
evidence of an association in the 3rd  
Dose-response  0 No evidence of a dose response 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence linking milk with IGFBP-2 levels and this 
suggests a negative association. 
 
  
Supplementary Table 10 – GRADE assessment of studies of milk and IGFBP3 levels 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 13 studies, 2 of which are 
RCTs 
2 A large number of observational studies with a smaller number of 
RCTs therefore start with score of 2 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious -1 Most studies have an unclear RoB 
Inconsistency Not serious 0 Studies seem to be consistent 
Indirectness Not serious 0 All studies looked at the effect of milk/dairy products on IGFBP-3 
levels 
Imprecision Serious 0 Several studies, some with large sample size (>1000) 
Publication bias Serious -1 Although not clearly evident there is likely to be publication bias in 
this area of research 
Factors increasing confidence 
Strength of association  +1 Combined p-value is very low 
Dose-response  0 Studies were not able to examine this robustly (RCTs based on a 
single dose/intervention, or food frequency questionnaires) 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence linking milk and IGFBP-3 levels, and this 
suggests a negative association  
 
  
Supplementary table 11 – GRADE assessment of studies of IGF-I levels and prostate cancer risk 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating many observational studies 2 All observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Moderate risk of bias 
Inconsistency Not serious 0 Studies show some effects in other directions, although prospective 
studies are mostly homogeneous 
Indirectness Not serious 0 All studies looked at circulating levels of IGF-I and their association 
with prostate cancer risk 
Imprecision Serious 0 Large number of studies some very large 
Publication bias Serious 0 No evidence of publication bias 
Factors increasing confidence 
Strength of association  0 Fairly weak association 
Dose-response  1 Some evidence of dose response  
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 3 
Statement of quality of evidence There is currently a moderate level of evidence linking IGF-I levels to prostate cancer 
risk, and this suggests a positive association 
 
  
Supplementary table 12 – GRADE assessment of studies of IGF-II levels and prostate cancer risk 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 10 observational studies 2 All observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Moderate risk of bias 
Inconsistency Not serious -1 Studies show strong effects in opposite directions 
Indirectness Not serious 0 All studies looked at circulating levels of IGF-II and their association 
with prostate cancer risk 
Imprecision Serious -1 Small number of studies some with conflicting results 
Publication bias Serious 0 No evidence of publication bias 
Factors increasing confidence 
Strength of association  0 Fairly weak association 
Dose-response  0 Possible dose response but inconsistency between studies 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence linking IGF-II levels with prostate cancer 
and the evidence suggests a positive association 
 
  
 Supplementary table 13 – GRADE assessment of studies of IGFBPI levels and prostate cancer risk 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 4 observational studies 2 All observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Moderate risk of bias 
Inconsistency Not serious -1 Studies show strong effects in opposite directions 
Indirectness Not serious 0 All studies looked at circulating levels of IGFBP-I and their 
association with prostate cancer risk 
Imprecision Serious -1 Small number of studies overall wide confidence intervals 
Publication bias Serious 0 No evidence of publication bias 
Factors increasing confidence 
Strength of association  0 Fairly weak association 
Dose-response  0 Possible dose response but inconsistency between studies 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence linking IGFBPI levels with prostate cancer 
risk and this suggests no association 
 
  
Supplementary table 14 – GRADE assessment of studies of IGFBP2 and prostate cancer risk  
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating 6 observational studies 2 All observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Moderate risk of bias 
Inconsistency Not serious -1 Studies show strong effects in opposite directions 
Indirectness Not serious 0 All studies looked at circulating levels of IGFBP-2 and their 
association with prostate cancer risk 
Imprecision Serious -1 Small number of studies overall wide confidence intervals 
Publication bias Serious 0 No evidence of publication bias 
Factors increasing confidence 
Strength of association  0 Fairly weak association 
Dose-response  0 Possible dose response but inconsistency between studies 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence linking IGFBP2 levels with prostate 
cancer. 
 
 
 
 
Supplementary table 15 – GRADE assessment of studies of IGFBP3 and prostate cancer risk  
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating Many observational studies 2 All observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Moderate risk of bias 
Inconsistency Not serious 0 Some studies show effects in opposite directions, prospective 
studies are largely homogeneous 
Indirectness Not serious 0 All studies looked at circulating levels of IGFBP-2 and their 
association with prostate cancer risk 
Imprecision Serious 0 Large number of studies some very large 
Publication bias Serious 0 No evidence of publication bias 
Factors increasing confidence 
Strength of association  0 Fairly weak association 
Dose-response  1 Some evidence of dose response  
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 3 
Statement of quality of evidence There is currently a moderate level of evidence linking IGFBP3 levels with prostate 
cancer. 
 
  
Supplementary table 16 – GRADE assessment of IGFI and advanced prostate cancer risk 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating observational studies 2 All observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Moderate risk of bias 
Inconsistency Not serious -1 Some outliers and difference between prospective and retrospective 
studies 
Indirectness Not serious 0 All studies looked at circulating levels of IGF-I and their association 
with advanced prostate cancer risk 
Imprecision Serious 0 Overall estimate quite precise 
Publication bias Serious 0 No evidence of publication bias 
Factors increasing confidence 
Strength of association  0 Fairly weak/no association 
Dose-response  0 Possible dose response but inconsistency between studies 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a low level of evidence linking IGFI levels with advanced prostate 
cancer risk. This evidence suggests a positive association. 
 
  
Supplementary table 17 – GRADE assessment of IGFBP3 and advanced prostate cancer risk 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating observational studies 2 All observational 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious 0 Moderate risk of bias 
Inconsistency Not serious 0 Some difference between prospective and retrospective studies 
Indirectness Not serious 0 All studies looked at circulating levels of IGFBP3 and their 
association with advanced prostate cancer risk 
Imprecision Serious 0 Overall estimate quite precise 
Publication bias Serious 0 No evidence of publication bias 
Factors increasing confidence 
Strength of association  0 Fairly weak/no association 
Dose-response  0 No evidence of dose response 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 2 
Statement of quality of evidence There is currently a low level of evidence linking IGFBP3 levels with advanced prostate 
cancer risk. Overall this evidence suggests no effect 
 
  
Supplementary table 18 – GRADE assessment of animal studies of the IGF pathway and prostate cancer risk 
Quality assessment Rating Adjustment to 
rating 
Notes 
No of studies/starting rating Experimental studies 4 All experimental 
Factors decreasing confidence 
Limitations in study design (risk 
of bias) 
Not serious -1 All unclear risk of bias 
Inconsistency Not serious 0 Each study was very different so unable to assess this 
Indirectness Not serious -1 Components of IGF pathway were knocked out or over expressed to 
very high levels, no comparable with normal distribution in humans, 
outcomes were tumour weight rather than incidence 
Imprecision Serious -1 Small number of animals in each experiment, not able to combine 
results across studies 
Publication bias Serious -1 Very likely to be publication bias 
Factors increasing confidence 
Strength of association  0 1 study showed a strong association but not replicated 
Dose-response  0 No evidence of dose response 
Confounders likely to minimise 
the effect 
 0 Unable to rule out confounding, may play a role 
Final numerical rating of quality of evidence 1 
Statement of quality of evidence There is currently a very low level of evidence from animal studies linking the IGF 
pathway with prostate cancer risk.  
 
*To aid the adjustment to ratings, high quality evidence scores 4 as a starting rating, low quality evidence scores 2 and very low quality evidence scores 1. 
The initial starting rating is then adjusted as +1 or -1 based on factors that increase (+1) or decrease (-1) confidence in the quality of evidence. The minimum 
final numerical rating of quality of evidence is 1.  
Supplementary Box 1. Search strategies used to search MEDLINE and EMBASE (28th March 2014). 
 
1. IGF1.tw 
2. IGF-1.tw 
3. IGFI.tw 
4. IGF-I.tw 
5. IGF1A.tw 
6. IGF-IA.tw 
7. IGF2.tw 
8. IGF-2.tw 
9. IGF-II.tw 
10. IGFII.tw 
11. IGF-IB.tw 
12. IGF1B.tw 
13. Insulin-like growth factor.tw 
14. exp Somatomedins/ 
15. somatomedin*.tw 
16. exp Insulin-Like Growth Factor Binding Proteins/ 
17. exp Receptors, Somatomedins/ 
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
19. (prostat* adj3 (neoplas* or cancer or carcinoma or tumo?r)).tw 
20. exp Prostatic Neoplasms/ 
21 19 or 20 
22. exp Prostatic Intraepithelial neoplasia/ 
23. exp Neoplasm Metastasis/ 
24. exp Neoplasm Invasiveness/ 
25. 23 or 24 
26. 21 and 25 
27. 21 or 22 or 26 
28. exp Dairy Products/ 
29. (dairy or milk or cheese* or butter or cream* or yog?urt).tw 
30. 28 or 29 
31. exp Pasteurization/ 
32. exp Dairying/ 
33. exp Food contamination/ 
34. (food* adj2 contaminat*).tw 
35. 33 or 34 
36. 30 and 35 
37. exp Recombinant Proteins/ 
38. exp Growth Hormone/ 
39. exp Cattle/ 
40. 37 and 38 and 39 
41. 30 or 31 or 32 or 36 or 40 
42. 18 and 27 
43. 42 not exp Therapeutic/ 
44. 43 not exp Review/ 
45. 18 and 41 
46. 45 not exp Therapeutic/ 
47. 46 not exp Review/ 
48. 27 and 41 
49. 48 not exp Therapeutic/ 
50. 49 not exp Review/ 
51. 18 and 27 and 41 
52. 51 not exp Therapeutic/ 
53. 52 not exp Review/ 
54. 44 or 47 or 50 or 53  
Note- for EMBASE use Therapy rather than Therapeutic MESH term 
 
 
 
 
 
 
 
  
 
Supplementary Box 2. Search strategies used to search CINAHL (30th March 2014). 
 
1. TI IGF1 or AB IGF1 
2. TI IGF-1 or AB IGF-1 
3. TI IGFI or AB IGFI 
4. TI IGF-I or AB IGF-I 
5. TI IGF1A or AB IGF1A 
6. TI IGF-IA or AB IGF-IA 
7. TI IGF2 or AB IGF2 
8. TI IGF-2 or AB IGF-2 
9. TI IGF-II or AB IGF-II 
10. TI IGFII or AB IGFII 
11. TI IGF-IB or AB IGF-IB 
12. TI IGF1B or AB IGF1B 
13. TI Insulin-like growth factor or AB Insulin-like growth factor 
14. (MH “Somatomedins”) 
15. TI Insulin-like growth factor binding protein or AB Insulin-like growth factor binding protein 
16. TI Somatomedins Receptors or AB Somatomedins Receptors 
17. TI Insulin-like growth factor receptor or AB Insulin-like growth factor receptor 
18. 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 or 16 or 17 
19. (MH “Prostatic Neoplasms”) 
20. T1 Prostatic Intraepithelial neoplasia or AB Prostatic Intraepithelial neoplasia 
21. T1 prostat* N3 (neoplas* or cancer or carcinoma or tumo?r) or AB prostat* N3 (neoplas* or cancer or carcinoma or tumo?r) 
22. (MH “Neoplasm Metastasis+”) 
23. (MH “Neoplasm Invasiveness”) 
24. 22 or 23 
25 19 or 21 
26. 24 AND 25 
27. 25 or 20 or 26 
28. (MH “Dairy Products+”) 
29. T1 dairy or milk or cheese* or butter or cream* or yog?urt or AB dairy or milk or cheese* or butter or cream* or yog?urt 
30. 28 or 29 
31. (MH “Pasteurization”) 
32. TI Dairying or AB Dairying 
33. (MH “Food Contamination+”) 
34. 30 AND 33 
35. (MH “Recombinant Proteins+”) 
36. TI Growth Hormone or AB Growth Hormone 
37. (MH “Cattle”) 
38. 35 AND 36 AND 37 
39. 30 or 31 or 32 or 34 or 38 
40. (MH “Therapeutics+”) 
41. (MH “Systematic Review”) 
42. (MH “Book Reviews”) 
43. (MH “Literature Review+”) 
44. 41 or 42 or 43 
45. 18 AND 27 
46. 45 not 40 
47. 46 not 44 
48. 18 AND 39 
49. 48 not 40 
50. 49 not 44 
51. 27 AND 39 
52. 51 not 40 
53. 52 not 44 
54. 18 AND 27 AND 39 
55. 54 not 40 
56. 55 not 44 
57. 47 or 50 or 53 or 56 
 
 
 
 
 
  
Supplementary Box 2. Search strategies used to search BIOSIS (31st March 2014). 
 
1. Topic=(IGF1 or IGF-1 or IGFI or IGF-I or IGF1A or IGF-IA or IGF2 or IGF-2 or IGF-II or IGFII or IGF-IB or IGF1B) 
2. Topic=(Insulin-like growth factor) 
3. Topic=(Somatomedins) 
4. Topic=(Insulin-like growth factor binding proteins) 
5. Topic=(Somatomedins Receptors) 
6. Topic=(Insulin-like growth factor receptor) 
7. 6 OR 5 OR 4 OR 3 OR 2 OR 1 
8. Topic=(prostat* neoplas* or prostat* cancer or prostat* carcinoma or prostat* tumo$r) 
9. Topic=(prostatic intraepithelial neoplasia) 
10. 9 OR 8 
11. Topic=(Neoplasm Metastasis or Neoplasm Invasiveness) 
12. 11 AND 8 
13. 12 OR 10 
14. Topic=(Dairy Products) 
15. Topic=(dairy or milk or cheese* or butter or cream* or yog$urt) 
16. Topic=(pasteurization or dairying) 
17. Topic=(Food contamination) 
18. 17 AND 14 
19. Topic=(Recombinant Proteins) 
20. Topic=(Growth Hormone) 
21. Topic=(Cattle) 
34. 33 AND 32 AND 31 
35. 34 OR 30 OR 28 OR 27 OR 26 
22. 21 AND 20 AND 19 
23. 22 OR 18 OR 16 OR 15 OR 14 
24. Topic=(Therapeutics) 
25. Topic=(Review) 
26. 13 AND 7 
27. 26 NOT 24 
28. 27 NOT 25 
29. 23 AND 7 
30. 29 NOT 24 
31. 30 NOT 25 
32. 23 AND 13 
33. 32 NOT 24 
34. 33 NOT 25 
35. 23 AND 13 AND 7 
36. 35 NOT 24 
37. 36 NOT 25 
38. 37 OR 34 OR 31 OR 28 
 
 
 
 
  
  
Supplementary Box 4. Risk of bias protocol. 
RoB Categories Specific questions used to answer RoB categories 
Milk-IGF (human): case/control   
Confounding Did the authors identify all possible confounding factors? Were 
these taken into account in the study design and/or analysis? Was 
there a large difference between the characteristics of cases and 
controls and if so, were they adjusted for? 
Selection of participants Were they selected in an acceptable way? Were they part of a 
defined population?  
Missing data Was the follow-up long enough for the outcome to occur? Was the 
follow-up complete enough? Were details given of those lost to 
follow up? E.g., was there a difference in those lost to follow-up 
compared to those included in the study? 
Measurement of outcome Did the authors use objective measurements? Were they validated? 
Was it accurately measured? 
Measurement of exposure 
(Focus on information recall from 
participants) 
Did the authors use objective measurements? Were they validated? 
Were all subjects classified into exposure groups using the same 
procedure? Was it accurately measured? Did this involve 
information recall from the participants? 
Selection of reported results Was the full protocol available? Were all aims of the study 
reported? Was the study free of selective reporting? 
Milk-IGF (human): RCT   
Sequence generation Was the way in which participants were selected at random 
acceptable? 
Allocation concealment Not applicable to this analysis as IGF levels cannot be directly 
influenced by the participants knowledge of the intervention they 
are participating in. 
Blinding of participants and personnel Not applicable to this analysis as IGF levels cannot be directly 
influenced by the participants knowledge of the intervention they 
are participating in. 
Blinding of outcome assessors Were the assessors blinded to the analysis they were undertaking? 
Incomplete data Was the follow-up long enough for the outcome to occur? Was the 
follow-up complete enough? Were details given of those lost to 
follow up? E.g., was there a difference in those lost to follow-up 
compared to those included in the study? 
Selective reporting Was the full protocol available? Were all aims of the study 
reported? Was the study free of selective reporting? 
IGF-PCa (human): all   
Confounding  
(IGF level studies focused on age & ethnicity; 
genetics studies focused on age, disease 
status of controls & ethnicity) 
Did the authors identify all possible confounding factors? Were 
these taken into account in the study design and/or analysis? Was 
there a large difference between the characteristics of cases and 
controls and if so, were they adjusted for? 
Selection of participants Were they selected in an acceptable way? Were they part of a 
defined population?  
Missing data (cohorts only) Was the follow-up long enough for PCa to occur? Was the follow-up 
complete enough? Were details given of those lost to follow up? 
Was there a difference in those lost to follow-up compared to those 
included in the study? 
Measurement of outcome (cohorts only) Did the authors use objective measurements? Were they validated? 
Was it accurately measured? 
Measurement of exposure Did the authors use objective measurements? Were they validated? 
Were all subjects classified into exposure groups using the same 
procedure? Was it accurately measured? 
Selection of reported results Was the full protocol available? Were all aims of the study 
reported? Was the study free of selective reporting? 
IGF-PCa (animal): all   
Confounding Did the authors identify all possible confounding factors? Were 
these taken into account in the study design and/or analysis? Was 
there a large difference between the characteristics of cases and 
controls and if so, were they adjusted for? 
Departures from intended observations Were the original aims of the study met? Did the results answer the 
original study question? 
Random housing of animals Were animals housed and kept in the same way to minimise 
environmental factors? 
Missing data Was the follow-up long enough for the outcome to occur? Was the 
follow-up complete enough? Were details given of those lost to 
follow up? E.g., was there a difference in those lost to follow-up 
compared to those included in the study? 
Measurement of outcome Did the authors use objective measurements? Were they validated? 
Was it accurately measured? 
Random outcome assessment of animals Were samples consistently taken from experimental and control 
groups at the same time?  
Selection of reported results Was the full protocol available? Were all aims of the study 
reported? Was the study free of selective reporting? 
 
